{'fraction_non_alphanumeric': 0.041561712846347604, 'fraction_numerical': 0.006297229219143577, 'mean_word_length': 5.115384615384615, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Discontinuing imatinib in chronic myeloid leukemia: don't try this at home

The use of the tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, and nilotinib has revolutionised the care of patients with chronic myeloid leukemia (CML) [1–3]. We now have more than 6 years of follow-up data on the IRIS study, and the frontline use of imatinib has been shown to be both highly efficacious and generally well-tolerated [4]. The large majority of newly diagnosed patients treated for CML in chronic phase achieve a complete cytogenetic remission (CCyR), and over time, most of these eventually achieve major molecular responses (MMR) and even complete molecular responses (CMR). However, cure has not yet been proven, and life-long therapy with imatinib is still the consensus recommendation [5].